Biosimilar Promising for Treatment of ERBB2+ Breast Cancer

Share this content:
Biosimilar Promising for Treatment of ERBB2+ Breast Cancer
Biosimilar Promising for Treatment of ERBB2+ Breast Cancer

(HealthDay News) -- A proposed biosimilar is comparable to trastuzumab for women with ERBB2-positive metastatic breast cancer, according to a study published online Dec. 1 in the Journal of the American Medical Association.

Hope S. Rugo, M.D., from the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, and colleagues compared the overall response rate and safety of a proposed trastuzumab biosimilar plus a taxane or trastuzumab plus a taxane in patients without prior treatment. Patients with metastatic breast cancer were randomized to a proposed biosimilar (230 patients) or trastuzumab (228 patients) with a taxane. The intention-to-treat population included 458 women, and the safety population included 493 women.

The researchers found that the overall response rate (ORR) at 24 weeks was 69.6 percent for the proposed biosimilar and 64 percent for trastuzumab; the ORR ratio and ORR difference were within the equivalence boundaries. No statistically significant difference was seen at week 48 for the proposed biosimilar versus trastuzumab for time to tumor progression, progression-free survival, or overall survival. Overall, 98.6 and 94.7 percent of the proposed biosimilar and trastuzumab groups had at least one adverse event, most commonly neutropenia (57.5 vs. 53.3 percent), peripheral neuropathy (23.1 vs. 24.8 percent), and diarrhea 20.6 vs. 20.7 percent).

"Among women with ERBB2-positive metastatic breast cancer receiving taxanes, the use of a proposed trastuzumab biosimilar compared with trastuzumab resulted in an equivalent overall response rate at 24 weeks," the authors write.

Several authors disclosed financial ties to the biopharmaceutical industry, including Mylan Inc. and Biocon Research Ltd., which funded the study.

Full Text
Editorial 1
Editorial 2

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs